The renal function trajectory in clinical trial design: challenges and opportunities

被引：0
|
作者：
Rosansky, Steven [1 ]
Glassock, Richard [2 ]
机构：
[1] Williams Jenning Brian Dorn Vet Adm Hosp, Dorn Res Inst, 6439 Garners Ferry Rd, Columbia, SC 29209 USA
[2] UCLA, David Geffen Sch Med, Dept Med, Los Angeles, CA USA
来源：
KIDNEY INTERNATIONAL | 2024年 / 106卷 / 04期
关键词：
D O I：
10.1016/j.kint.2024.07.023
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The changes in renal function over time as surrogate endpoints for new drug trials are complicated by many factors, including the oftenexpected initial decrease in estimated glomerular filtration rate when a new drug is started. Two articles in the journal address this challenge, but multiple other challenges are explored in this commentary. To maximize the benefits of expensive new drugs that may slow decline in renal function, these drugs should be reserved for those patients who have a high probability of rapid loss of kidney function.
引用
收藏
页码：565 / 568
页数：4
相关论文
共 50 条
  • [31] Design for manufacturability: Challenges and opportunities
    Sylvester, D
    2005 6TH INTERNATIONAL CONFERENCE ON ASIC PROCEEDINGS, BOOKS 1 AND 2, 2005, : 32 - 34
  • [32] DESIGN ROADMAPPING: CHALLENGES AND OPPORTUNITIES
    Kim, Euiyoung
    Yao, Shun
    Agogino, Alice Merner
    ICED 15, VOL 6: DESIGN METHODS AND TOOLS - PT 2, 2015,
  • [33] Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial
    Goodman, Phyllis J.
    Tangen, Catherine M.
    Darke, Amy K.
    Arnold, Kathryn B.
    Hartline, JoAnn
    Yee, Monica
    Anderson, Karen
    Caban-Holt, Allison
    Christen, William G.
    Cassano, Patricia A.
    Lance, Peter
    Klein, Eric A.
    Crowley, John J.
    Minasian, Lori M.
    Meyskens, Frank L.
    TRIALS, 2016, 17
  • [34] Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial
    Phyllis J. Goodman
    Catherine M. Tangen
    Amy K. Darke
    Kathryn B. Arnold
    JoAnn Hartline
    Monica Yee
    Karen Anderson
    Allison Caban-Holt
    William G. Christen
    Patricia A. Cassano
    Peter Lance
    Eric A. Klein
    John J. Crowley
    Lori M. Minasian
    Frank L. Meyskens
    Trials, 17
  • [35] Cancer: Clinical challenges and opportunities
    Beer, DG
    METHODS OF MICROARRAY DATA ANALYSIS IV, 2005, : 9 - 20
  • [36] Clinical Bioinformatics: challenges and opportunities
    Riccardo Bellazzi
    Marco Masseroli
    Shawn Murphy
    Amnon Shabo
    Paolo Romano
    BMC Bioinformatics, 13
  • [37] Clinical Genomics: Challenges and Opportunities
    Vijay, Priyanka
    McIntyre, Alexa B. R.
    Mason, Christopher E.
    Greenfield, Jeffrey P.
    Li, Sheng
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2016, 26 (02): : 97 - 113
  • [38] Opportunities and challenges for clinical registries
    Kandel, Himal
    Gillies, Mark C.
    Watson, Stephanie L.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2023, 51 (06): : 651 - 652
  • [39] OPPORTUNITIES AND CHALLENGES AHEAD FOR THE TRIAL BAR
    SHRAGER, DS
    TRIAL, 1983, 19 (08): : 4 - 4
  • [40] Factors influencing the renal function trajectory following MMF introduction in renal transplantation: Interim results of trancept, a prospective observational global clinical trial.
    Meier-Kriesche, Herwig-Ulf
    Merville, P.
    Heemann, U.
    Dantal, J.
    Sanz, A.
    Berthoux, F.
    Zhu, Y. H.
    Tedesco, H.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 526 - 526
12345